Customize your JAMA Network experience by selecting one or more topics from the list below.
A new committee focused on digital health technologies, including artificial intelligence, machine learning, and virtual reality, will advise the US Food and Drug Administration (FDA) on the risks, benefits, and clinical outcomes linked with these tools, the agency announced.
The Digital Health Advisory Committee will be composed of 9 voting members who will also provide insight into the barriers and unintended consequences of introducing novel technologies into the health care system, thus helping to guide the FDA’s regulation of such products.The team will begin its role in 2024.
The FDA is looking forward to having a “committee of experts throughout the field who can help ensure our regulation of these exciting tools maintains an appropriate pace while working within parameters of safety and effectiveness standards,” Troy Tazbaz, the director of the FDA’s Digital Health Center of Excellence, said in a statement.
Published Online: November 1, 2023.doi:10.1001/jama.2023.21177
Harris E.New FDA Advisory Team to Focus on AI, Other Digital Health Technologies.JAMA.
2023;330(19):1828.doi:10.1001/jama.2023.21177
© 2023
Artificial Intelligence Resource Center.
